Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biomarkers predicting response to mepolizumab in chronic rhinosinusitis with nasal polyps
NL-OMON59502Phase 4Recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Aug 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of mepolizumab in chronic rhinosinusitis with nasal polyps (CRSwNP), sponsored by Amsterdam University Medical Center. Primary endpoint: Identification of cell and molecular biomarkers correlated with individual response. Started Aug 2024; status: recruiting.
02
Drugs
mepolizumab
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)
Beyond the preview
Go deeper on NL-OMON59502.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59502.